Mark Nelson

Mar 29, 2024 | digitalcommons.library.tmc.edu | John McNeil |John Mcneil |Robyn L. Woods |Mark Nelson |Christopher Reid

BACKGROUND: Information on the use of aspirin to increase healthy independent life span in older persons is limited. Whether 5 years of daily low-dose aspirin therapy would extend disability-free life in healthy seniors is unclear.

Mar 29, 2024 | digitalcommons.library.tmc.edu | John McNeil |John Mcneil |Mark Nelson |Robyn L. Woods |Jessica E. Lockery

BACKGROUND: In the primary analysis of the Aspirin in Reducing Events in the Elderly (ASPREE) trial, now published in the Journal, we report that the daily use of aspirin did not provide a benefit with regard to the primary end point of disability-free survival among older adults. A numerically higher rate of the secondary end point of death from any cause was observed with aspirin than with placebo.

Nov 9, 2023 | bottomlineinc.com | Mark Nelson |Tom Cioffi

Macular degeneration, also known as age-related macular degeneration (ARMD), is a degenerative disease of the macula, a part of the retina. Vision loss begins with central vision, which mainly affects reading, but it can later spread into peripheral vision, and can lead to profound visual disability if not treated. There are two types of ARMD: dry (nonexudative) and wet (exudative). The term wet refers to leakage of fluid and blood from abnormal vessels below the retina (neovascularization).

Jul 14, 2023 | pubmed.ncbi.nlm.nih.gov | Mark Nelson |Nirvik Pal |Kertia MD |Miklos D Kertia

Skip to main page content Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day?